We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Scinai Immunotherapeutics Ltd (SCNI) ADR Each Representing 400 Ord Shares SPON

Sell:$3.32 Buy:$3.54 Change: $0.52 (17.22%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$3.32
Buy:$3.54
Change: $0.52 (17.22%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$3.32
Buy:$3.54
Change: $0.52 (17.22%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Contact details

Address:
Jerusalem Biopark
2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM
00000
Israel
Telephone:
+972 (8) 9302529
Website:
https://www.scinai.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SCNI
ISIN:
US09073Q3039
Market cap:
$2.50 million
Shares in issue:
3.35 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Mark Germain
    Chairman of the Board
  • Amir Reichman
    Chief Executive Officer, Director
  • Uri Ben-Or
    Chief Financial Officer
  • Elad Mark
    Chief Operating Officer
  • Tamar Ben-Yedidia
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.